Measles vaccination rates falling provincewide, CBC analysis finds

Provincewide measles immunization for seven-year-olds fell from 90% in 2015 to 70% in 2024. Canada lost measles elimination status after a nationwide outbreak of >6,000 confirmed/probable cases starting Oct 2024, and B.C.'s northeast (largest local outbreak ~400 cases) saw seven-year-old coverage drop from 95% to 66% (two-year-olds 78% to 64%). Other notable declines: Thompson Cariboo Shuswap 90%→63% and Okanagan 85%→60%. Analysts flag data gaps in the B.C. registry and recommend merging electronic health records with immunization data to improve coverage tracking.

Analysis

The key investment implication is that this is a geographically concentrated public‑health problem with strong local feedback loops rather than a sustained national demand shift. Localized loss of herd immunity tends to produce sharp, time‑limited catch‑up windows (we should model 3–9 month surges in vaccine administration and related services) followed by a reversion to baseline; that dynamic favors players that can flex distribution volume or capture one‑off onboarding contracts rather than firms that rely on sustained pricing power.

Second‑order winners will be logistics/distribution and enterprise health IT vendors that can win provincial modernization contracts — procurement cycles here are multi‑year but lumpy and high‑value. Conversely, vaccine manufacturers face limited upside in list prices (MMR is a mature, low‑margin product) so their revenue bump is likely volume‑and-timing dependent and small relative to market caps; clinical services (walk‑in clinics, small community providers) will see volatility and operational strain.

Risk taxonomy: near term (days–weeks) outbreak trajectories and supply bottlenecks; medium term (3–12 months) is a policy/capital spending cycle when provinces decide whether to fund registry integration or mass clinics; long term (12–36 months) is legal/political risk around data privacy and budget reallocation that can stall IT rollouts. A reversal of the catch‑up surge can come quickly if school‑entry mandates or mass clinics are implemented (consuming pent‑up demand) or if vaccine shipment constraints occur, creating temporary scarcity and then sharp normalization.

Contrarian read: the market should not treat vaccine makers as a structural growth trade here — upside is front‑loaded and capped. The more durable and asymmetrical opportunity is in vendors that win systems‑integration and distribution tenders (lumpy, high gross‑margin contracts) and in short‑duration tactical trades around expected 3–9 month volume spikes.

Key Decisions for Investors

• Long MCK (McKesson) — 6–12 month tactical position: accumulate on weakness with a 12–18% upside target and a 6–8% stop. Rationale: captures short‑term volume and distribution fee flow during catch‑up window; payback concentrated in quarters. Risk: single‑quarter margin pressure if volumes normalize; supply chain/time lags could push realization into next quarter.
• Small overweight MRK (Merck) — 3–6 month trade: size 1–2% of portfolio, target +8–12%, stop −6%. Rationale: modest revenue lift from incremental MMR doses and public‑sector purchases; low downside given diversified pharma portfolio. Risk: limited pricing power makes upside capped and earnings impact likely immaterial to fair value.
• Long ORCL (Oracle/Cerner exposure) via 12–36 month call spread (e.g., buy 2yr calls, sell higher strike) — directional play for provincial EHR/immunization registry integration. Expect 15–30% upside if provinces fund rollouts; downside limited to premium paid for spread. Catalyst: provincial IT contract announcements and federal funding allocations.
• Pair trade: long MCK (distribution) / short small community clinic operator or regional outpatient services (select names) — 3–9 month horizon. Rationale: distributors gain from centralized procurement and mass clinics; small operators face margin compression and operational overload. Trade provides positive carry if backlog resolves and clinics’ margins normalize downward.